Cargando…

Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis

BACKGROUND: Currently approved biologic therapies for moderate-to-severe ulcerative colitis have well-established efficacy. However, many patients fail to respond or lose response, leading to dose escalation or treatment switching. OBJECTIVE: We sought to identify real-world evidence on dose escalat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Harpreet, Wilson, Liam, Tencer, Tom, Kumar, Jinender
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968424/ https://www.ncbi.nlm.nih.gov/pubmed/36855750 http://dx.doi.org/10.2147/CEOR.S391413

Ejemplares similares

A Systematic Review of the Economic and Health-Related Quality of Life Impact of Advanced Therapies Used to Treat Moderate-to-Severe Ulcerative Colitis
por: Cichewicz, Allie, et al.
Publicado: (2023)

Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World Data
por: Black, Christopher M., et al.
Publicado: (2016)

A146 THE EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN PATIENTS WITH ULCERATIVE COLITIS
por: Albino, L, et al.
Publicado: (2022)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

Dose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review
por: Panaccione, Remo, et al.
Publicado: (2023)

Real-World Patient Experience of Switching Biologic Treatment in Inflammatory Arthritis and Ulcerative Colitis – A Systematic Literature Review
por: Luttropp, Karin, et al.
Publicado: (2020)

Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis
por: Long, Millie D., et al.
Publicado: (2022)

Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis
por: Wagner, Frank, et al.
Publicado: (2023)

Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison
por: Cohan, Stanley, et al.
Publicado: (2021)

Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis
por: Savelkoul, Edo H J, et al.
Publicado: (2022)

Dose Escalation of Biologics in Biologic-Naïve Patients With Ulcerative Colitis: Outcomes From the ODESSA-UC Study
por: Ghosh, Sabyasachi, et al.
Publicado: (2023)

Indirect costs associated with ulcerative colitis: a systematic literature review of real-world data
por: Constantin, Joelle, et al.
Publicado: (2019)

Ustekinumab in ulcerative colitis‐ insights from the real‐world data
por: Veisman, Ido, et al.
Publicado: (2022)

Patient and Neurologist Preferences in the United States for Relapsing-Remitting Multiple Sclerosis Treatments: Findings from a Discrete Choice Experiment
por: Kumar, Jinender, et al.
Publicado: (2021)

Real-World Effectiveness of Vedolizumab Dose Escalation in Patients With Inflammatory Bowel Disease: A Systematic Literature Review
por: Patel, Dipen, et al.
Publicado: (2022)

Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis
por: Uchida, Genta, et al.
Publicado: (2023)

Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation
por: Politis, Dimitrios S., et al.
Publicado: (2019)

Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results
por: Teich, Niels, et al.
Publicado: (2020)

Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study
por: Safroneeva, Ekaterina, et al.
Publicado: (2015)

A Randomized, Double‐Blind, Placebo‐Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX‐02 in Healthy Subjects
por: Leubitz, Andi, et al.
Publicado: (2021)

Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States
por: Zhdanava, Maryia, et al.
Publicado: (2023)

Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure
por: Bressler, Brian, et al.
Publicado: (2018)

Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis
por: Lucaciu, Laura A., et al.
Publicado: (2021)

Real-World Long-Term Remission Maintenance for 10 Years With Thiopurines in Ulcerative Colitis
por: Matsumoto, Satohiro, et al.
Publicado: (2021)

Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis: a real world intention-to-treat analysis
por: Sood, Ajit, et al.
Publicado: (2019)

Real de-escalation or escalation in disguise?
por: Banys-Paluchowski, Maggie, et al.
Publicado: (2023)

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
por: D’Amico, Ferdinando, et al.
Publicado: (2019)

Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario
por: Zingone, Fabiana, et al.
Publicado: (2020)

Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis
por: Ishida, Natsuki, et al.
Publicado: (2021)

The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study
por: Ye, Byong Duk, et al.
Publicado: (2021)

Significance of diagnosis and prognosis for appendiceal orifice inflammation in ulcerative colitis: a real-world study
por: Deng, Peng, et al.
Publicado: (2022)

Real-world effectiveness of ustekinumab for patients with ulcerative colitis: a systematic review and meta-analysis
por: Uchida, Genta, et al.
Publicado: (2023)

Real‐world use of endoscopic and histological indices in ulcerative colitis: Results of a global survey
por: Nardone, Olga Maria, et al.
Publicado: (2023)

Real-World Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients: A Retrospective Cohort Study
por: State, Monica, et al.
Publicado: (2023)

Use of corticosteroids for remission induction therapy in patients with new-onset ulcerative colitis in real-world settings
por: Okayasu, Motohiro, et al.
Publicado: (2019)

Remote Monitoring of Patient-Reported Outcomes in Ulcerative Colitis: A Prospective Real-World Pilot Study
por: Sebastian, Shaji, et al.
Publicado: (2019)

Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford
por: Pulusu, Samba Siva Reddy, et al.
Publicado: (2020)

Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States
por: Long, Millie D, et al.
Publicado: (2020)

Lesson from Real-World Experience: Optimal Treatment with Anti-Tumor Necrosis Factor for Ulcerative Colitis
por: Chun, Jaeyoung
Publicado: (2021)

Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China
por: Huang, Kaituo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5ev7da18sl9l3rlb8hv2k9q0tp